Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec appointment
confidence 92%
filed 2026-09-14
EX-99
The exhibit discloses the Board's approval of multiple executive appointments: (i) appointment of a new Managing Director & Chief Executive Officer (subject to RBI approval), (ii) re-appointment of Mr. V. Srinivasa Rangan as Executive Director, and (iii) appointment of Mr. Jimmy Tata as Executive Director. These are material governance events affecting the bank's senior leadership structure. While the MD/CEO appointment is conditional on RBI approval, the Board has formally approved the candidates and remuneration, making this a significant disclosure of executive succession and leadership changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-14
Item 5.02
The Board appointed Mary C. Henry as a director effective October 5, 2026, expanding the Board from five to six members. This is a clear director appointment under Item 5.02(d). While the disclosure also mentions standard director compensation arrangements, the principal disclosed action is the appointment itself, making this an exec_appointment event that is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-14
Item 5.02
The disclosure centers on the appointment of Robert Plenge, M.D., Ph.D., to BioMarin's Board of Directors effective September 10, 2026, with assignment to the Science and Technology Committee. While the filing also describes standard director compensation and an RSU grant valued at $400,000, the principal disclosed action is the appointment of a new director to the board, making this an exec_appointment event. Board composition changes are material to investors' assessment of governance and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-14
The 6-K discloses the appointment of Mr. Michael Davern as a director of Pelagos Insurance Capital Limited, effective September 14, 2026, to serve on the Board and its Risk Committee and Investment Committee. This is a director-level appointment at a public company, which is material to investors assessing board composition and governance. The disclosure includes his qualifications, background in insurance underwriting and actuarial work, and compensation arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-14
Item 5.02
Derek Walker was elected to the Board of Directors on September 12, 2026, effective immediately, to fill a vacancy. The disclosure centers on the appointment action itself, including his background, qualifications, and board tenure. While the appointment was made pursuant to GPC Fund's nominee rights under a Board Nominee Agreement, the principal disclosed event is the election of a director to the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-14
Item 5.02
Mr. Steven Hershkowitz is being reinstated as Executive Vice President and Chief Revenue Officer effective September 14, 2026, resuming his previous role and responsibilities after a brief resignation on September 8, 2026. While this involves a reinstatement rather than a new appointment, the principal disclosed action is a person taking (or resuming) an executive role with material operational significance—CRO responsibilities and direct reports are being reassigned to him. The compensation details (base salary of $480,000 and incentive opportunity of $320,000.16) are secondary to the reinstatement itself, making this an appointment event rather than a pure compensation disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-14
Item 5.02
Tami Reller was appointed to Health Catalyst's Board of Directors effective October 1, 2026, filling a newly created seat as the Board expanded from six to seven directors. She was also appointed as Audit Committee Chair and member of the Compensation Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-11
Item 5.02
The filing discloses two executive appointments effective October 1, 2026: Mandeep Chawla to a newly created role of Group President, Global Markets, and Todd Ankenmann to Chief Financial Officer. While Chawla's departure from the CFO role is mentioned, the principal disclosed actions are the appointments themselves, supported by detailed compensation arrangements (salary increases, CTI targets, and equity awards for both executives). This is a material leadership restructuring affecting the company's executive team.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-11
EX-99.1
The exhibit announces shareholder approval of the appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of Agomab's Board of Directors at the Company's Special and Extraordinary General Shareholders' Meeting on September 11, 2026. This is a discrete executive appointment event requiring disclosure under Item 5.02 of Form 8-K (or equivalent 6-K disclosure). Board appointments are material to investors as they affect governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-09-11
Item 5.02
Mario Gross was appointed as President of Building Envelope, effective September 11, 2026, succeeding Jake Gosa who resigned from the position. Gross was promoted from Chief Supply Chain Officer to lead the major business segment.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-09-11
The filing discloses that Mr. Ruihong Ma was elected as Chairman of the Board and Chief Financial Officer effective September 10, 2026, filling vacancies created by the resignations of Mr. Jiancong Huang (director and Chairman) and Ms. Xiaofen Jin (CFO). While the filing also reports two departures, the principal disclosed action is the appointment of Ma to two senior executive roles. This is material as it represents a significant leadership change affecting both the board chair and financial officer positions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 55%
filed 2026-09-11
Item 5.02
Upon completion of the merger on September 8, 2026, Jonathan Violin was appointed as Chief Executive Officer and the board was reconstituted with new directors, representing a material leadership transition and governance restructuring incident to the merger completion.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-11
EX-99.1
The exhibit discloses three senior executive appointments effective September 4, 2026: Vlad Shpilsky as Group Head, Global Technology and Solutions; Renu Gupta as Senior Executive Vice President and Chief Strategy and Commercial Officer (joining the Senior Executive Team); and Paul Whitehead as Senior Executive Vice President, Global Corporate Services (joining the Senior Executive Team). Although Taylan Turan's departure is also mentioned, the principal disclosed action is the appointment of three named executives to material roles, making this an exec_appointment event. The material change report explicitly identifies these as "senior leadership appointments" affecting the Bank's strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-11
Item 5.02
Anand S. Kangala was appointed as a Class I director and member of the Audit and Ethics Committee effective September 10, 2026. His appointment is material given his extensive digital transformation and technology leadership experience at major companies (Trex, Home Depot, Lowe's), which aligns with the company's strategic priorities around digital capabilities and technology modernization.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-11
The 6-K announces the appointment of Ms. Joyce Zheng as Chief Accounting Officer of Aurelion Inc., effective September 14, 2026, replacing the previous acting CAO Ms. Yuki Xu. The disclosure includes detailed background on the appointee's qualifications, including 10+ years of experience in corporate finance, public accounting, and SEC reporting, as well as her role in a prior company's Nasdaq IPO. This is a clear executive appointment of a named officer to a material financial reporting role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-11
Item 5.02
Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to a Settlement Agreement. Chae has been serving as Co-Chief Executive Officer since May 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-11
Item 5.02
The filing discloses both the resignation of Stephen M. Silver as CEO, Chair, and Director, and the concurrent appointment of Ashley Zumwalt-Forbes as CEO and Chair. While both events occur, the principal disclosed action centers on the appointment of Zumwalt-Forbes to the top executive role (CEO and Chair), making this an exec_appointment. The departure is secondary context. This is material as it represents a change in principal executive leadership of the SPAC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-11
Item 5.02
The filing discloses the appointment of Jason Hawkins to the Board of Directors effective immediately on September 8, 2026, to fill a vacancy. While two directors (Shalom Hirschman and Riad El-Dada) also resigned on the same date, the substantive disclosure centers on the appointment of Hawkins, a capital markets executive with 25+ years of experience and current Chairman/CEO of Intrusion Precious Metals Corp. (a significant minority shareholder). This is a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-11
EX-99.1
The exhibit discloses the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee in August 2026. While the filing also mentions stock option grants and warrant exercises, the principal disclosed action is the appointment of a director to a leadership governance role. Dr. Duncan's extensive biotechnology and capital markets background, combined with his appointment to chair the audit committee, represents a material governance event affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-11
Item 5.02
Christopher Ensey was appointed as Chief Executive Officer and Board member of Volato, replacing Matthew Liotta who resigned from the CEO position. The appointment of a new chief executive officer is material to investors' assessment of company leadership and strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-11
Item 5.02
Oportun Financial Corp appointed William Franklin as Chief Financial Officer, effective September 8, 2026. Franklin brings over 20 years of financial leadership experience, including prior service as CFO of Consumer Banking at Discover Financial Services. The appointment includes a base salary of $500,000, 75% target bonus, $200,000 signing bonus, and 276,626 RSUs.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-11
Item 5.02
Five new directors (Anthony M. Abate, Douglas S. Aron, Maria V. Gordon, Steven J. Pully, and William P. Wall) were appointed to the Board of Directors effective on the closing date of the restructuring transaction, with William P. Wall designated as Non-Executive Chair. This reconstitution of the board reflects significant governance changes following completion of the major restructuring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-10
Item 5.02
The filing discloses the Board's unanimous appointment of Brantley J. Standridge as President of Huntington Bancshares and The Huntington National Bank, effective September 8, 2026, representing a material promotion within the executive hierarchy. While the disclosure also includes compensatory arrangements (salary and incentive increases), the principal disclosed action centers on the appointment to the President role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-10
Item 5.02
The Board adopted a succession plan on September 10, 2026, appointing Michael C. Colwell as president and COO effective October 1, 2026, and as president, CEO, and director effective January 2, 2027. The plan also includes Jeffrey L. Powell's transition to executive chairman and Jonathan W. Painter's resignation as director and chairman.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
The filing discloses the appointment of Ray S. Greenberg as a director of Quaint Oak Bancorp, Inc. effective September 9, 2026, with an initial term expiring at the 2029 annual meeting. He was simultaneously appointed to the Company's Audit Committee. This is a clear director appointment under Item 5.02(d), which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
DexCom appointed Glenn S. Boehnlein as a director effective September 10, 2026, with assignment to the Operations & Innovation Committee and Audit Committee. Boehnlein brings extensive healthcare and finance leadership experience, including prior service as Vice President and Chief Financial Officer of Stryker Corporation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-10
Item 5.02
David H. Watkins was appointed President and Chief Executive Officer effective September 30, 2026, succeeding Pablo Castanos who resigned from the position. Watkins, a director since 2009 with over 50 years of mining industry experience, represents a significant executive leadership change for the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-10
Item 5.02
The filing discloses both the departure of Aditya J. Gandhi as Vice President and Chief Accounting Officer (effective September 11, 2026) and the appointment of Daniel Ackerman as Senior Vice President, Interim Chief Accounting Officer on the same date. While both events occur, the principal disclosed action centers on the Board's appointment of Ackerman to fill the Chief Accounting Officer role, making this an exec_appointment. The departure is contextual background explaining why the appointment was necessary.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
The disclosure centers on the appointment of Susan L. Main to Fortive's Board of Directors effective September 9, 2026, with concurrent appointment to the Audit Committee. While the section also mentions standard non-employee director compensation and an indemnification agreement, the principal disclosed action is the director taking a role. The Board's determination of her independence and audit committee financial expert status further confirms this is an appointment event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-09-10
EX-99.1
The press release announces the appointment of Brad Rogers as President, Chief Executive Officer, and Director of North American Construction Group Ltd., effective December 1, 2026. This is a material executive appointment at the highest level of the organization, following a multi-month global search process. The appointment of a new CEO is a significant governance event that would affect a reasonable investor's assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-09-10
Item 5.02
Sanjay Subramanian was appointed as Chief Financial Officer effective September 9, 2026, succeeding Ivor Macleod who retired from the role. Mr. Subramanian's compensation package includes a $500,000 base salary, $20,000 sign-on bonus, equity grants, and severance provisions, reflecting his extensive capital markets and M&A experience in biotechnology.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
Village Farms International appointed Hamid Shekarchi as Interim Chief Financial Officer effective September 10, 2026, succeeding Stephen Ruffini. Shekarchi's employment agreement includes a C$567,000 base salary, bonus, and equity grants, with detailed severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors effective September 8, 2026, increasing the Board from 10 to 11 directors. Dr. Zimmermann brings 30+ years of regulatory affairs and quality expertise, directly supporting the company's planned BLA submission in Q4 2026 and commercial readiness.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-10
Item 5.02
TransMedics appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective September 21, 2026, succeeding Gerardo Hernandez. Araujo brings over 20 years of public-company finance leadership from GE HealthCare, 3M, and GE, with a compensation package including $590,000 base salary, $200,000 sign-on bonus, and approximately $3.5 million in equity awards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
The filing discloses the appointment of Vijay Iyengar, M.D. to the Board of Directors of Whitehawk Therapeutics, effective September 9, 2026, as a Class III director. While the disclosure also includes compensatory details (stock option grant of 76,080 shares and base annual retainer of $40,000), the principal action is the appointment itself. Dr. Iyengar's extensive oncology and corporate strategy background from Incyte and Novartis makes this a material governance event affecting the composition of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
The disclosure centers on the appointment of Brian Goldenberg as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective September 8, 2026. While the section also notes that CEO Luis Goldner will no longer serve as Principal Financial Officer, the principal action disclosed is the appointment of a named executive to a key financial officer role. This is material as it affects the registrant's financial leadership and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-10
Item 5.02
The filing discloses the appointment of two directors, James Lim and Edward Park, to the Board of Reborn Coffee on September 3, 2026, following an increase in Board size from seven to eight members. This is a clear executive appointment event under Item 5.02, and board composition changes are material to investors' assessment of governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-10
The filing's principal disclosure is the appointment of Brian R. Meadows as a director of Caring Brands, Inc., effective September 4, 2026, approved by the Board on September 3, 2026. While the filing also discloses a consulting agreement with Myall Luna Ventures Inc. (of which Meadows is President) and director compensation arrangements (annual option grants of 25,000 shares), the core event is Meadows taking a director role. The appointment of a qualified director with CFO experience at multiple public companies is material to investors' assessment of the company's governance and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-10
Item 5.02
Jason Knoblauch was reinstated as Chief Financial Officer and designated principal financial officer on September 9, 2026, following resolution of a Delaware Court of Chancery restraining order that had prevented him from working in that role. While the filing also discloses that David Smith stepped down from the Interim CFO position, the principal disclosed action is Knoblauch's reinstatement to the CFO role, making this an executive appointment. The reinstatement of a CFO following litigation and a settlement agreement is material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-10
Item 5.02
The filing discloses the Board's designation of Ms. Julie Bradshaw as interim principal financial officer and Ms. Debbie Angelico as interim principal accounting officer, effective September 8, 2026, following Mark Chiplock's resignation as CFO. While this is technically an interim appointment, the designation of individuals to assume the principal financial and accounting officer roles is a material executive appointment that would affect investor assessment of the company's financial leadership during the CFO search process.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-10
Item 5.02
The disclosure centers on the appointment of two current executives to new senior positions: Michael Moore (EVP, COO) to President, Service Division, and Chris Berg (EVP, Fleet Management) to President, Rental Division, effective September 9, 2026. While these are internal promotions rather than external hires, they represent material changes in executive roles and organizational structure tied to the Company's new Platform Operating Model. The principal action disclosed is the assumption of new positions by named officers.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-10
Item 5.02
Frederick Hundt was appointed as interim Chief Financial Officer on September 3, 2026, assuming the role of principal financial officer and principal accounting officer. Although the appointment is interim pending a permanent search, the elevation of an existing officer to CFO—a C-suite executive position—is a material executive appointment that would affect investor assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-09
Item 5.02
Kevin R. Mandia was elected as a director of Amazon and appointed to the Audit Committee and Security Committee. The appointment includes a restricted stock unit award of 4,086 shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-09
Item 5.02
The disclosure centers on the appointment of Ms. Virginia Gambale to the Board of Directors and the Audit Committee, effective September 8, 2026, along with the Board's resolution to expand from three to four directors. While the section also mentions Mr. Smith's resignation from the Audit Committee and director services agreements for both Ms. Gambale and Mr. Grinberg, the principal disclosed action is the appointment of a new director and committee member. This is material as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Ball Corporation's Board of Directors elected two new directors, Darlene Nicosia and Sherry Buck, effective September 21, 2026. Both bring substantial executive experience—Nicosia as CEO of Maker's Pride with 30+ years in food and beverage operations, and Buck as former CFO with extensive financial and industrial expertise across multiple Fortune 500 companies. Both were appointed to key board committees including Finance, Audit, and Nominating/Corporate Governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Matthew E. Garth was appointed as Executive Vice President and Chief Financial Officer of Cornerstone Building Brands effective September 1, 2026, with a compensation package including $750,000 base salary, 90% target bonus, $200,000 sign-on bonus, and 202,777.78 Class B Profit Units. Garth brings 30+ years of financial leadership experience from prior roles at major companies including Dentsply Sirona, Scotts Miracle-Gro, Minerals Technologies, and Alcoa.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Century Therapeutics appointed Joseph Truitt as a director and member of the Compensation Committee, effective September 9, 2026. The Board expanded from six to seven directors to accommodate the appointment. Truitt brings significant biotechnology leadership experience as CEO of iECURE and Chairman of Larimar Therapeutics, and will receive an initial option grant of 148,000 shares and a $40,000 annual retainer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
BJ's Restaurants appointed Christopher W. Brandt and James D. White as independent directors to its Board of Directors, effective September 3, 2026. Both appointees bring substantial experience from senior leadership roles at major restaurant and consumer companies including Chipotle, Jamba Juice, Bloomin' Brands, Taco Bell, CAVA, and Simply Good Foods, and will serve on key board committees including Governance and Nominating, and Compensation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-09
EX-99.1
The press release announces the appointment of Ron Freund, the Company's Chief Financial Officer, as Chief Executive Officer effective September 23, 2026. While the exhibit also discloses Eli Yaffe's retirement as CEO and his subsequent appointment as a director, the principal disclosed action is Freund's appointment to the CEO role. The appointment of a new CEO is material to investors as it represents a significant leadership transition at the company level.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 96%
filed 2026-09-09
Item 5.02
Stephen J. Bye was appointed as President and Chief Executive Officer and director of WW International, effective on or prior to November 27, 2026, with the Board unanimously electing him as director and increasing board size from six to seven members. The appointment includes a comprehensive employment agreement with significant compensation ($850,000 base salary, $1.5M signing bonus, $1M signing RSU award, and $5.1M initial equity grant), representing a material C-suite leadership transition.
View raw filing on EDGAR →